Navigation Links
Powerful free radical causes lung damage from oxygen therapy
Date:10/5/2010

AUGUSTA, Ga. The most toxic free radical appears responsible for much of the lung damage that can result from oxygen therapy in the critically ill or injured, Medical College of Georgia researchers report.

Within just a few days, ventilators and oxygen chambers used to significantly increase oxygen levels can also dramatically increase levels of peroxynitrite, an oxidant powerful enough to break down DNA and cause proteins to malfunction, said Dr. Yunchao Su, pharmacologist in the MCG Schools of Medicine and Graduate Studies.

Oxygen toxicity is the most severe side effect of oxygen therapy in newborns and adults. The lungs take the brunt of the damage, which can include inflammation, hemorrhaging and swelling that may result in death or chronic lung problems, said Su, corresponding author of the study published in the Journal of Biological Chemistry.

"We knew it was bad but we did not know why," Su said. The good news is they may also have a solution.

Researchers found that within five days, mice placed in small oxygen chambers that mimic oxygen levels given in intensive care have dramatically elevated levels of peroxynitrite in their lungs. Free radicals, such as peroxynitrite, result from oxygen use and are safe at low levels. While it's a given that oxygen therapy produces free radicals, the significant increase in peroxynitrite was not known.

The trouble begins when high oxygen levels prompt endothelial cells that line blood vessels and tiny airs sacs in the lung to make more nitric oxide, the precursor of peroxynitrite. At high levels, nitric oxide, most often a helpful compound, combines with other free radicals produced by excess oxygen use to form the powerful peroxynitrite. "As oxygen levels increase, nitric oxide levels increase and so peroxynitrite levels do as well," Su said.

But he appears to have identified a break point in the destructive cycle. Su found that in the face of high oxygen levels, the enzyme that makes nitric oxide binds with the protein actin to produce more nitric oxide. So he developed a compound, peptide 326, that interferes with their binding and the excess peroxynitrite levels that typically follow. Su used the binding site itself as a cue for the peptide design after trying many existing compounds, including smoke, to break the bond.

Su's long term goal is for peptide 326, or something similar, to be used in patients likely after the first few days of oxygen therapy. Much as health care providers monitor blood oxygen long term to ensure sufficient levels, they could also monitor peroxynitrite levels. "It's only after several days of steady increases that the level becomes destructive," Su noted.

MCG scientists are already using peptide 326 in mice receiving oxygen therapy.


'/>"/>

Contact: Toni Baker
tbaker@mcg.edu
706-721-4421
Medical College of Georgia
Source:Eurekalert  

Related medicine news :

1. Breaching the blood-brain barrier to create powerful new tools for fighting cancer
2. doeLegal and Zapproved Sign Alliance to Add Legal Hold Pro to Suite of Powerful Online Legal Solutions
3. New Book Reveals the Powerful and Undermining Impact of Stress on Good Decision Making and What Leaders Can Do About It
4. Powerful People Often Too Optimistic About Task Time
5. Adapting to clogged airways makes common pathogen resist powerful drugs
6. American Council on Exercise (ACE) Study Reveals Kettlebells Provide Powerful Workout in Short Amount of Time
7. Plant compound resveratrol shown to suppresses inflammation, free radicals in humans
8. Lumenis Announced Today it is Sponsoring the Endometriosis Foundation of America's Symposium 'Advancing the Art and Science of Endometriosis: Stem Cells to Radical Excision Surgery'
9. Henry Ford Health System goes radical: Creating the hospital of the future
10. Cigarette smoke causes harmful changes in the lungs even at the lowest levels
11. Scientists closer to finding what causes the birth of a fat cell
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Powerful free radical causes lung damage from oxygen therapy
(Date:12/8/2016)... ... December 08, 2016 , ... With the increasing demand for dental ... Your Mouth?” (WIYM) campaign to inform dentists and patients about the safety issues related ... and prosthetic market in the U.S. is projected to reach $6.4 billion in 2018 ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... technologies and development solutions for drugs, biologics and consumer health products, today announced ... was set up in 2006 as a non-profit organization to unite pharmaceutical and ...
(Date:12/8/2016)... ... 08, 2016 , ... Healthcare is in flux. The GOP ... the mass media launching of story movements to highlight what's most unfair about ... experiences; such a movement can generate the network power to improve healthcare policies ...
(Date:12/8/2016)... ... December 08, 2016 , ... Peter Zipp Insurance, an ... around the greater Phoenix metropolitan region, is announcing a charity event to provide ... the Homeless Youth Connection is to promote community awareness of the ongoing needs ...
(Date:12/7/2016)... ... 07, 2016 , ... DrugDev again demonstrated its dedication to reducing ... the early adopters completing EU-U.S. Privacy Shield Certification from the U.S. Department of Commerce. ... sides of the Atlantic with a mechanism to comply with EU data protection requirements ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... 2016   TriNetX , the health research ... signed a membership agreement to join the ... new cures. The TriNetX network is ... patients globally, biopharmaceutical companies and contract research organizations ... design, site selection, patient recruitment, and collaborative research ...
(Date:12/8/2016)... , Dec. 8, 2016  Valeant Pharmaceuticals International, ... VRX) ("Valeant") today announced positive results from a ... to assess the safety and efficacy of IDP-118 ... of plaque psoriasis. Within the ... moderate to severe psoriasis, IDP-118 showed statistical significance ...
(Date:12/8/2016)... 8, 2016  EIP Pharma, LLC ( www.eippharma.com ... for neflamapimod (previously code named VX-745), with the ... trials that demonstrated significant Alzheimer,s disease relevant pharmacological ... and Study 303 (6-week treatment) are the subject ... Disease (CTAD) scientific conference in San ...
Breaking Medicine Technology: